Ibogaine is a Class A controlled substance in the United Kingdom under the Misuse of Drugs Act 1971 and is listed under Schedule 1 of the Misuse of Drugs Regulations 2001, meaning it has no recognised medical use and carries the strictest legal penalties for possession, supply, or production. Last verified: April 2026.

Current Legal Status

Ibogaine falls under Class A of the Misuse of Drugs Act 1971 — the same category as heroin, cocaine, and MDMA. Class A carries the highest criminal penalties available under UK drug law.

Under Schedule 1 of the Misuse of Drugs Regulations 2001, ibogaine is classified as having no accepted medical or therapeutic use. Schedule 1 substances cannot be prescribed by doctors, dispensed by pharmacists, or lawfully possessed by patients. Research involving Schedule 1 substances requires a specific Home Office licence, which is rarely granted and involves a substantial regulatory burden.

Penalties for Class A offences in England and Wales:
  • Possession: Up to 7 years imprisonment, an unlimited fine, or both.
  • Supply or intent to supply: Up to life imprisonment, an unlimited fine, or both.
  • Production or importation: Up to life imprisonment, an unlimited fine, or both.

Penalties in Scotland and Northern Ireland operate under the same Act but sentencing practice may vary.

Religious or sacramental exemptions: The UK does not currently recognise any religious carve-out for ibogaine or for iboga plant material. Unlike some jurisdictions, there is no equivalent to the US Religious Freedom Restoration Act framework that has been applied to certain plant-based substances. Possession for ceremonial purposes remains a criminal offence.

Iboga plant material: While ibogaine the isolated alkaloid is explicitly controlled, the legal status of Tabernanthe iboga root bark and other iboga-containing plant preparations is treated as controlled where it is intended for human consumption, as the psychoactive compound is the same substance. The Psychoactive Substances Act 2016 provides an additional layer, broadly prohibiting the supply of any psychoactive substance not otherwise exempted.

Treatment Centers

No legal ibogaine treatment clinics operate in the United Kingdom. Because ibogaine is a Schedule 1 substance with no recognised medical application, there is no lawful pathway for a clinic to administer it to patients, and no Home Office licence framework exists for therapeutic use outside of formal clinical trials.

Any facility claiming to offer ibogaine therapy within the UK is operating outside the law and carries serious risks for both providers and patients. People in the UK seeking ibogaine treatment overwhelmingly travel abroad to access it.

For clinics operating in legal jurisdictions, see our full international clinic directory.

How People Access Ibogaine in the United Kingdom

The following describes how people in the UK currently access ibogaine. This is factual reporting and does not constitute a recommendation or endorsement of any course of action.

  • Medical travel to Europe: The most common route is travelling to clinics in Portugal, the Netherlands, or other European countries where ibogaine is either unscheduled or operates in a regulated grey area. Portugal and the Netherlands are the most frequently cited destinations for UK residents.
  • Travel further afield: Some individuals travel to clinics in Mexico, Costa Rica, or other jurisdictions where ibogaine is explicitly legal or licensed. These destinations have well-established clinic infrastructure.
  • Underground or grey-market access: Some people access ibogaine through informal networks within the UK. This carries significant legal risk (Class A possession or supply) and serious safety risks given the absence of any medical oversight, cardiac screening, or emergency infrastructure.
  • Research participation: A very small number of participants may access ibogaine through formally approved clinical research studies. Any such study would require a Home Office Schedule 1 research licence and NHS or university ethics approval. Opportunities are extremely limited.
Safety note for those travelling abroad: Returning to the UK with ibogaine in your possession — including residual amounts in luggage or on your person — constitutes a Class A possession offence. UK Border Force regularly screens for controlled substances.

Recent Legal Developments

The UK's scheduling of ibogaine has not changed since its placement under the Misuse of Drugs Act 1971. However, several developments in the broader landscape are worth noting:

  • Psychedelic research expansion (2023–2026): Growing academic interest in psychedelic-assisted therapies — particularly psilocybin and MDMA — has led to increased Home Office Schedule 1 research licences for those substances. This has opened some discussion about whether ibogaine should be re-evaluated, particularly given international evidence on its use in opioid use disorder treatment.
  • NICE and opioid treatment guidelines: The National Institute for Health and Care Excellence (NICE) has not reviewed ibogaine for any therapeutic indication. There is no formal MHRA (Medicines and Healthcare products Regulatory Agency) pathway currently open for ibogaine approval.
  • US federal momentum: The passage of the Ibogaine Therapy for Veterans Act in the United States in late 2024, and subsequent FDA engagement with ibogaine research, has attracted attention in UK policy circles and among addiction medicine professionals. Some UK researchers have cited this as potential grounds for pushing for UK Schedule 1 research licensing.
  • Parliamentary questions: Individual MPs have raised questions about psychedelic-assisted therapy in parliamentary proceedings, though none have specifically targeted ibogaine rescheduling as of April 2026.
  • Drug policy reform pressure: Organisations including Transform Drug Policy Foundation continue to advocate for broader reform of the Misuse of Drugs Act framework, but no concrete legislative proposals to reschedule ibogaine are currently before Parliament.

Risks of Seeking Treatment in the United Kingdom

Because no legal treatment infrastructure exists in the UK, people who access ibogaine domestically face a specific combination of legal and medical risks:

Legal risks

  • Possession of ibogaine in any quantity is a Class A offence carrying up to 7 years imprisonment.
  • Anyone who assists another person in obtaining or taking ibogaine — including by sourcing, funding, or being present — may face supply or conspiracy charges.
  • There is no "personal use" exemption under UK law that reduces a Class A possession charge to a civil penalty, unlike some European jurisdictions.

Medical and safety risks

  • No cardiac screening: Ibogaine prolongs the QT interval and can cause fatal cardiac arrhythmias. In a medical setting, a baseline ECG, cardiac history review, and supervised monitoring are considered the minimum standard of care. Underground access provides none of these safeguards.
  • No drug interaction screening: Ibogaine has dangerous and potentially fatal interactions with opioids, SSRIs, stimulants, and many other substances. Without a prescribing physician, these interactions go unscreened.
  • No emergency response: Sessions typically last 24–36 hours. In an unmonitored setting, there is no means of accessing emergency care without simultaneously exposing all parties to criminal liability — a dynamic that has contributed to deaths in informal settings worldwide.
  • No quality control: Ibogaine obtained through illicit channels has no guaranteed purity, concentration, or content. Adulteration or mislabelling is a recognised risk.
  • Psychological risks: Ibogaine produces intense, prolonged psychedelic experiences. Without pre-screening for personal and family psychiatric history, there is risk of precipitating or exacerbating psychosis or other serious mental health conditions.
If you are considering ibogaine for addiction treatment: Speak with your GP or an addiction specialist about legal treatment options available in the UK, including opioid substitution therapy (methadone, buprenorphine), naltrexone, and evidence-based psychosocial interventions. These carry no legal risk and have established safety profiles.

Frequently Asked Questions

Yes. Ibogaine is a Class A controlled substance under the Misuse of Drugs Act 1971 and is listed under Schedule 1 of the Misuse of Drugs Regulations 2001. Possession, supply, production, and importation are all criminal offences. Class A is the highest level of control under UK drug law, carrying penalties including up to life imprisonment for supply offences.
No. Ibogaine is a Schedule 1 substance under the Misuse of Drugs Regulations 2001, meaning it has no recognised medical use and cannot be prescribed by any doctor in the UK, regardless of their specialty or the patient's circumstances. It cannot be dispensed by pharmacists and cannot lawfully be held or administered in any clinical setting without a specific Home Office research licence — and even then, only within an approved research protocol, not as routine patient care.
No legal ibogaine clinics operate in the United Kingdom. Any facility claiming to administer ibogaine therapeutically in the UK would be operating outside the law. People seeking ibogaine treatment from the UK typically travel to clinics in Portugal, the Netherlands, Mexico, or Costa Rica, where ibogaine is legal or operates in a regulated framework. See our international clinic directory for options in legal jurisdictions.
The iboga plant is not separately listed in the Misuse of Drugs Act, but plant material containing ibogaine — including root bark — is treated as controlled when intended for human consumption due to the presence of the scheduled alkaloid. Additionally, the Psychoactive Substances Act 2016 broadly prohibits the supply of any psychoactive substance not explicitly exempted. Importing or supplying iboga root bark for consumption purposes carries significant legal risk under both pieces of legislation.
There are currently no concrete legislative proposals to reschedule or legalise ibogaine in the UK. Growing interest in psychedelic-assisted therapy — particularly around psilocybin — has opened broader conversations about drug scheduling reform, and international developments such as US federal research into ibogaine have attracted some attention from UK researchers and clinicians. However, moving a substance from Schedule 1 to a prescribable schedule requires a formal MHRA/NICE review process and political will. As of April 2026, neither is in evidence for ibogaine specifically.
The NHS offers a range of evidence-based treatments for opioid use disorder and other substance dependencies. These include opioid substitution therapy with methadone or buprenorphine (Subutex/Suboxone), naltrexone for alcohol and opioid dependence, and structured psychosocial interventions including cognitive behavioural therapy and contingency management. Your GP can refer you to local drug treatment services, or you can self-refer to community drug services in your area. Frank (talktofrank.com) provides a treatment finder and confidential helpline.

Informational only. Not legal advice. Laws change. Verify with a licensed attorney before making any decisions.